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Abstract
We previously carried out a genome-wide association study of generalized vitiligo (GV) in non-
Hispanic whites, identifying 13 confirmed susceptibility loci. In this study, we re-analyzed the
genome-wide data set (comprising 1,392 cases and 2,629 controls) to specifically test association
of all 33 GV candidate genes that have previously been suggested for GV, followed by meta-
analysis incorporating both current and previously published data. We detected association of
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three of the candidate genes tested: TSLP (rs764916, P = 3.0E-04, odds ratio (OR)= 1.60; meta-P
for rs3806933= 3.1E-03), XBP1 (rs6005863, P = 3.6E-04, OR= 1.17; meta-P for rs2269577=
9.5E-09), and FOXP3 (rs11798415, P = 5.8E-04, OR= 1.19). Association of GV with CTLA4
(rs12992492, P = 5.9E-05, OR= 1.20; meta-P for rs231775= 1.0E-04) seems to be secondary to
epidemiological association with other concomitant autoimmune diseases. Within the major
histocompatibility complex (MHC), at 6p21.33, association with TAP1-PSMB8 (rs3819721, P =
5.2E-06) seems to derive from linkage disequilibrium with major primary signals in the MHC
class I and class II regions.
INTRODUCTION
Vitiligo is the most frequent pigmentation disorder, with a prevalence of ~0.38% in
Caucasians. In generalized vitiligo (GV), the predominant form of the disorder, patches of
depigmented skin result from autoimmune destruction of melanocytes (Birlea et al., 2010).
GV is a “complex disorder,” involving combinatorial pathogenic effects of multiple
susceptibility genes and unknown environmental triggers (Spritz, 2010). Moreover, patients
with GV and also their close relatives have elevated frequencies of certain other
autoimmune diseases (Alkhateeb et al., 2003; LaBerge et al., 2005), suggesting that these
autoimmune diseases involve shared susceptibility factors.
Numerous genetic studies of biological candidate genes for GV have been published
(reviewed in Spritz (2010)). Whereas some genes, such as HLA and PTPN22, have had
consistent support from multiple studies, most other genes have not. Many studies of the
latter group have been limited by small sample sizes and thus insufficient power, failure to
adequately correct for multiple testing, and very likely population stratification artifacts, all
of which greatly increase the risk of false-positive “associations” (Hirschhorn et al., 2002;
Freedman et al., 2004); accordingly, over the past few years, candidate gene studies have
been largely replaced by genome-wide association studies (GWASs), which can avoid or
control for these causes of false association.
We recently carried out a GWAS of GV in non-Hispanic white subjects, identifying and
confirming at least 13 different loci that contribute to GV risk, almost all of which have
immunoregulatory functions (Jin et al., 2010a, b); 2 of these loci and 1 additional signal in
the major histocompatibility complex (MHC) were also identified in a Chinese GWAS of
GV (Quan et al., 2010). To detect additional GV susceptibility loci that were not identified
by the GWAS, we took advantage of our very large genome-wide data set, which has been
subjected to rigorous data quality control and correction for population stratification, to
specifically test for association of 33 biological candidate genes that have been previously
implicated in GV (ACE, AIRE, CAT, CD4, CLEC11A, COMT, CTLA4, C12orf10, DDR1,
EDN1, ESR1, FAS, FBXO11, FOXD3, FOXP3, GSTM1, GSTT1, IL1RN, IL10, KITLG,
MBL2, NFE2L2, PDGFRA-KIT, PTGS2, STAT4, TAP1-PSMB8, TGFBR2, TNF, TSLP,
TXNDC5, UVRAG, VDR, and XBP1; Supplementary Table S1 online), followed by a meta-
analysis incorporating both the current and available previously published data, when
possible. Three of the loci tested (namely FOXP3, TSLP, and XBP1) showed evidence of
primary association with GV, and the meta-analysis strongly supported XBP1 as a true GV
susceptibility locus. A fourth locus, CTLA4, seems to be secondarily associated with GV,
deriving from primary association with other autoimmune diseases that are
epidemiologically associated with GV. The apparent association of TAP1-PSMB8 with GV
is secondary to linkage disequilibrium (LD) with primary associated loci located elsewhere
in the MHC class I and class II gene regions.
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RESULTS
The 33 gene regions and candidate single-nucleotide polymorphisms (SNPs) analyzed are
shown in Table 1. Our sample set of non-Hispanic whites (N= 1,392 cases, N= 2,629
controls; see Jin et al. (2010a)) provided 80% power to detect significant association at odds
ratios (ORs) ≥1.21, 1.22, and 1.26 for corresponding minor allele frequencies of 0.5, 0.3,
and 0.2, respectively, assuming a multiplicative model. P-values for association were
considered using two different Bonferroni multiple-testing adjusted significance thresholds.
The first, less conservative, threshold was based on the 33 loci tested (0.05/33; P<1.52E-03
(0.05/ 33). The second, more stringent, threshold was based on 80 blocks of LD tested,
calculated using D′ (0.05/80; P<6.25E-04). For each allelic association, we calculated a
meta-analysis P-value (referred to as “meta-P” herein) on the basis of all available current
and previously published data, in most cases imputing the previously reported SNP in the
current genome-wide data set. Many of these previous reports did not apply appropriate
multiple-testing correction; for each of these, we calculated and applied the requisite
correction.
ACE
In 120 GV cases and 429 controls from Korea, Jin et al. (2004b) reported an association
with the ACE region insertion–deletion (indel) rs1799752 (ACE I/D) (allelic P= 1.2E-02).
Three subsequent studies failed to replicate this association: a UK study of 106 non-
Hispanic white cases and 174 controls (Akhtar et al., 2005), an Indian study of 125 cases
and 156 controls (Dwivedi et al., 2008), and a Turkish study of 48 cases and 50 controls
(Pehlivan et al., 2009). Indel rs1799752 is not in HapMap, but is in complete LD (D′ = 1,
r2= 0.86) with rs4343 (Abdollahi et al., 2008). In this study, we observed no association
with rs4343 (allelic P= 0.17); however, a meta-analysis of rs4343 and published data for
rs1799752 could not be performed. Overall, we observed no association of any of 24 SNPs
(14 imputed) spanning the ACE region (chr17:61,544,434–61,579,979).
AIRE
Genetic linkage analysis of non-Hispanic white GV families identified a minor linkage peak
in 21q that includes AIRE (Fain et al., 2003), but re-analysis of the same families found no
association of GV with seven SNPs spanning the AIRE region (Jin et al., 2007). In a small
UK non-Hispanic white cohort of 86 cases and 63 controls, Tazi-Ahnini et al. (2008)
reported an association of vitiligo with the AIRE-synonymous SNP rs1800521 (allelic P=
1.4E-05), which was not included in the previous linkage study and is not in HapMap. In
this study, we observed no association of any of the 29 SNPs (22 imputed) spanning the
AIRE region (chr21:45,695,763–45,723,110), including the 7 SNPs studied previously (Jin
et al., 2007).
CAT
In a US non-Hispanic white cohort of 230 GV cases and 188 controls, Casp et al. (2002)
reported genotypic (P= 1.6E-02, Bonferroni-adjusted P= 3.2E-02), but not allelic (P= 0.18,
Bonferroni-adjusted P= 0.36), association of the CAT SNP rs769217, and in a UK non-
Hispanic white cohort of 166 vitiligo cases and 169 controls, Gavalas et al. (2006) also
reported association (allelic P= 2.2E-02, genotypic P= 3.0E-02) of rs769217. However,
studies of rs769217 from Korea (Park et al., 2006), India (Em et al., 2007), and China (Liu
et al., 2010) found no association. In this study, we observed no association with rs769217
(allelic P= 0.21, genotypic P= 0.26), and the meta-analysis of SNP rs769217 demonstrated a
consistent high-risk allele across the six studies, but failed to achieve the study significance
threshold, either overall (meta-P= 2.1E-02, OR= 1.08) or in an analysis limited to the three
non-Hispanic white cohorts (meta-P= 0.12, OR= 1.09). Liu et al. (2010) reported an
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association with 5′-flanking SNP rs7943316 (allelic P= 1.0E-03, genotypic P= 6.0E-03), but
we found no association with rs7943316 (allelic P= 0.45, meta-P= 2.2E-02, OR= 1.10).
Overall, we observed no association with any of the 48 SNPs (30 imputed) spanning the
CAT region (chr11:34,450,478–34,498,603).
CD4
In 144 GV cases and 144 controls from Iran, Zamani et al. (2009) reported an association
with a pentanucleotide variable number of tandem repeats polymorphism (VNTR)
(CD4-1188) (Bonferroni-corrected P= 2.0E-02 for allele A4 and Bonferroni-corrected P=
1.0E-02 for genotype A4/X). In European non-Hispanic whites, VNTR CD4-1188 is in
strong LD with rs2855534 (Kristiansen et al., 2004), which in this study did not achieve the
study significance threshold (P= 5.0E-02). Overall, we observed no association with any of
the 28 SNPs (14 imputed) spanning the CD4 region (chr12:6,872,512–6,939,850).
CLEC11A
In 51 GV cases and 118 controls from Taiwan, Lan et al. (2009) reported an association
with rs7246355 and rs13866 (false-discovery rate-adjusted P= 3.2E-02 for both SNPs). In
this study, we observed no association with rs7246355 (allelic P= 0.48); rs13866 is not in
HapMap and thus cannot be imputed. Overall, we observed no association of any of the 12
SNPs (6 imputed) spanning the CLEC11A region (chr19:51,216,605–51,233,979).
COMT
In 749 GV cases and 763 controls from China, Li K et al. (2009) reported an association
with nonsynonymous SNP rs4680 (genotypic P= 3.0E-03, allelic P= 1.1E-03). In this study,
we observed no association with rs4680 (genotypic P= 0.47, allelic P= 0.14, meta-P= 0.26,
OR= 1.03) or with any of the 20 SNPs spanning the COMT region (chr22:19,919,263–
19,962,496).
CTLA4
Most CTLA4 association studies have assayed the nonsynonymous SNP rs231775 (+49 A/
G). In 74 non-Hispanic white cases and 173 controls, Kemp et al. (1999) reported an
association of vitiligo with a CTLA4 intragenic microsatellite in strong LD with rs231775
(uncorrected P= 2.0E-02), principally in the subgroup of cases with other concomitant
autoimmune diseases (uncorrected P= 1.0E-04). Similar findings were reported in two case–
control studies from Turkey (Itirli et al., 2005; Pehlivan et al., 2009). Similarly, Blomhoff et
al. (2005) observed association only in the subgroup of European non-Hispanic white GV
cases with other autoimmune diseases (rs231775, rs3087243, rs11571302, and rs7565213
uncorrected allelic P= 8.0E-02, P= 3.0E-02, P= 2.0E-02, and P= 1.0E-02, respectively). In
contrast, three other studies in non-Hispanic whites found no association for all
comparisons: a family-based study (LaBerge et al., 2008) and two case–control studies
(Birlea et al., 2009); a fourth study, in Indians (Deeba et al., 2010), found no association of
CTLA4 with nonsegmental vitiligo. Meta-analysis of all studies of GV in non-Hispanic
whites indicated significant association of rs231775 (and near significance for other SNPs in
LD) in the subgroup of GV cases with other concomitant autoimmune diseases (Birlea et al.,
2009).
In this study, rs231775 was associated with GV in both the all-cases group (P= 2.6E-04,
meta-P= 2.5.0E-04, OR= 1.15) and in the subgroup of cases with other autoimmune diseases
(P= 1.2E-04, meta-P= 4.4E-06, OR= 1.37). In contrast, the study significance threshold was
not achieved for the subgroup of cases with only vitiligo (P= 2.0E-02, meta-P= 6.0E-02,
OR= 1.10). Overall, we analyzed 104 SNPs (87 imputed) spanning the CTLA4 region
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(chr2:204,694,351–204,799,697) and observed association across multiple SNPs
(Supplementary Figure S1 online) in both the all-cases group and the subgroup of cases with
other autoimmune diseases, both groups showing maximum association with the CTLA4
promoter region SNP rs12992492 (P= 5.9E-05, OR= 1.20 and P= 7.3E-05, OR= 1.36,
respectively). By contrast, no CTLA4 region SNP achieved the study significance threshold
in the subgroup of patients with isolated GV without other autoimmune diseases
(Supplementary Figure S1 online). Furthermore, comparison of the subsets of GV cases with
versus without other autoimmune diseases was significant for both rs231775 (P= 2.1E-02,
meta-P= 1.3E-02) and rs12992492 (P= 2.9E-02). Taken together, these results support
previous conclusions that association of CTLA4 with GV is secondary, driven by primary
genetic association of CTLA4 with other autoimmune diseases that are epidemiologically
associated with vitiligo.
C12orf10
In 124 GV cases and 325 controls from Estonia, Philips et al. (2010) reported an association
with C12orf10 promoter SNP rs1465073 (allelic P= 3.8E-02). In this study, we observed no
association of GV with rs1465073 (allelic P= 0.23), and the meta-analysis was not
significant (meta-P= 0.27, OR= 1.03). Overall, we observed no association of GV with any
of the 11 SNPs (8 imputed) spanning the C12orf10 region (chr12:53,683,470–53,705,964).
DDR1
In 220 cases and 409 controls from Korea, Kim et al. (2010) found no association of vitiligo
with any of 6 DDR1 markers. However, in 212 trios from Brazil, Silva de Castro et al.
(2010), reported association of rs2267641 (allelic P= 1.0E-02, Bonferroni-corrected P=
3.0E-02), rs4618569 (P= 2.0E-02, Bonferroni-corrected P= 6.0E-02), and rs1049623 (P=
5.0E-02, Bonferroni-corrected P= 0.15). These investigators also reported genotypic
association of rs2267641 in an independent Brazilian cohort of 134 cases and 134 controls
(genotypic P= 4.0E-02, allelic P= 0.87); however, that result was rendered not significant by
application of appropriate multiple-testing correction (Bonferroni-corrected genotypic P=
0.12). In this study, we observed no association with rs2267641 (allelic P= 0.32, genotypic
P= 0.89), and the meta-analysis was also not significant (allelic meta-P= 0.27, OR= 1.04;
genotypic meta-P= 8.0E-02, OR= 1.10). Overall, we observed no association with any of the
41 SNPs (14 imputed) spanning the DDR1 region (chr6:30,486,465–30,872,931).
EDN1
In 312 cases and 313 controls from Korea, Kim et al. (2007) reported association with an
EDN1 haplotype defined by rs2071942 (intron 4 G/A) and rs5370 (exon 5 G/T) (P=
3.1E-08). A study of 51 cases and 118 controls from Taiwan (Lan et al., 2009) did not
replicate association with either of these SNPs or with the rs2071942–rs5370 haplotype
(false-discovery rate-adjusted allelic P= 0.78 for each SNP). We could not test rs2071942–
rs5370 haplotypes, as rs2071942 is not in Hap-Map; however, we observed no association
with rs5370 (allelic P= 0.24, meta-P= 0.17, OR= 1.05) or with any of the 30 SNPs (17
imputed) spanning the EDN1 region (chr6:12,280,529–12,302,426).
ESR1
In 120 GV cases and 254 controls from Korea, Jin et al. (2004a) reported an association
with the ESR1 intronic SNP rs2234693 (allelic P= 3.4E-02). In this study, we observed no
association with rs2234693 (allelic P= 0.20, meta-P= 0.38, OR= 1.01) or with any of the 73
SNPs (24 imputed) spanning the ESR1 region (chr6:152,118,454–152,429,406).
Birlea et al. Page 5
J Invest Dermatol. Author manuscript; available in PMC 2011 September 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FAS
In 750 cases and 756 controls from China, Li et al. (2008) and Li M et al. (2009) reported an
association of vitiligo with the FAS 5′-flanking SNP rs2234767 (−1377A>G) (allelic P=
7.0E-03, genotypic P= 6.0E-03). SNP rs2234767 is not in HapMap, but is correlated (D′ =
0.89, r2= 0.66) with rs1800682 (Kim et al., 2009). In this study, we observed no association
with rs1800682 (allelic P= 7.1E-02, genotypic P= 0.17) or with any of the 30 SNPs (20
imputed) spanning the FAS region (chr10:90,740,288–90,780,541).
FBXO11-MSH6
The involvement of FBXO11 (previously, VIT1) in vitiligo was suggested on the basis of
differential expression analysis (Le Poole et al., 2001). Putative mutations in the adjacent
MSH6 gene were reported in a single patient with early-onset colorectal cancer, systemic
lupus erythematosus, and vitiligo (Rahner et al., 2008). In this study, we observed no
association with any of 12 SNPs spanning the FBXO11-MSH6 region (chr2:48,029,061–
48,142,814).
FOXD3
Alkhateeb et al. (2002) found linkage of GV with microsatellite markers in chromosome
1p31.3 in a multi-generation, non-Hispanic white family with GV and other autoimmune
diseases, and subsequently reported cosegregation of GV with a unique variant
(rs41285370) in the 5′-flanking region of FOXD3 (−639G>T) (Alkhateeb et al., 2005). SNP
rs41285370 is not in HapMap and thus cannot be imputed; accordingly, we analyzed 10
SNPs (7 imputed) spanning the FOXD3 region (chr1:63,778,730–63,795,797) and observed
no association.
FOXP3
FOXP3 is the defective gene in the X-linked recessive immunodysregulation,
polyendocrinopathy, and enteropathy multiple autoimmune disease syndrome (OMIM
#304790), which can include GV. We analyzed 37 SNPs (30 imputed) across the FOXP3
region (chrX:49,093,528–49,373,620), observing tight LD across a 242-kb block that
includes FOXP3, PPP1R3F, GAGE10, and GAGE1 (Supplementary Figure S2A online).
Within FOXP3, the greatest significance was for promoter region SNP rs3761547 (P=
1.8E-03, OR= 1.23). However, within the LD block, the greatest significance was for
rs11798415 within GAGE10 (P= 5.8E-04, OR= 1.19) and for rs5906843 within GAGE1 (P=
6.2E-04). Forward stepwise regression analysis of the four most-strongly associated markers
in the region (namely rs11798415, rs5906843, rs5906777, and rs4824755) indicated that all
associations are secondary to rs11798415.
GSTM1
In 310 GV cases and 549 controls from Korea, Uhm et al. (2007) reported an association
with a GSTM1 region indel polymorphism (genotypic P= 1.2E-06, OR= 2.04, Bonferroni-
corrected P= 2.5E-06). A subsequent study in a Chinese cohort failed to replicate this
association (Liu et al., 2009). This GSTM1 indel variant is not in HapMap; accordingly, we
analyzed 4 SNPs (2 imputed) spanning the GSTM1 region (chr1:110,220,418–110,241,366)
and observed no association.
GSTT1
In 749 GV cases and 763 controls from China, Liu et al. (2009) reported an association with
indel rs2234953 (GSTT1+/−) (genotypic P= 1.1E-03, Bonferroni-adjusted genotypic P=
3.3E-03), although a study of 310 cases and 449 controls from Korea found no association
with the same marker (Uhm et al., 2007). Indel rs2234953 is not in HapMap; accordingly,
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we analyzed 3 SNPs (all imputed) spanning the GSTT1 region (chr22:24,371,141–
24,394,284) and found no evidence of association.
IL1RN
In 48 cases and 50 controls from Turkey, Pehlivan et al. (2009) reported an association with
an IL1RN intronic VNTR polymorphism (allelic P= 1.6E-02, genotypic P= 1.5E-02), a
result rendered not significant by appropriate multiple-testing correction (allelic and
genotypic P= 6.0E-02). In the European non-Hispanic white population, this VNTR is in
complete LD with SNP rs419598 (IL1RN+2018) (Hutyrová et al., 2002). In this study, we
observed no association with rs419598 (allelic P= 0.48, genotypic P= 0.50) or with any of
the 54 SNPs (46 imputed) spanning the IL1RN region (chr2:113,875,138–113,896,592).
IL10
In 83 GV cases and 101 controls from Saudi Arabia, Abanmi et al. (2008) reported
association with IL10 5′-flanking SNPs rs1800871 (−819C/T; genotypic P= 2.0E-02) and
rs1800872 (−592C/A) (which are in perfect LD). In this study, we observed no association
of GV with either rs1800871 or rs1800872 (genotypic P= 0.49), and the meta-analysis was
also not significant (meta-P= 0.27, OR= 1.03). Overall, we observed no association with any
of the 20 SNPs (12 imputed) spanning the IL10 region (chr1:206,935,948–206,955,839).
KITLG
In 51 GV cases and 118 controls from Taiwan, Lan et al. (2009) reported an association
with the intronic SNP rs11104947 (false-discovery rate-adjusted P= 3.6E-02). In this study,
rs11104947 was not significant (P= 6.0E-02, meta-P= 1.4E-02, OR= 1.17), and we observed
no association with any of the 34 SNPs (28 imputed) spanning the KITLG region
(chr12:88,881,569–88,984,238).
MBL2
In 40 GV cases and 50 controls from Turkey, Onay et al. (2007) reported an association
with the nonsynonymous MBL2 SNP rs1800450 (allelic P= 1.0E-04, genotypic P= 1.0E-03).
A study of 92 cases and 94 controls from India (Dwivedi et al., 2009) failed to replicate this
association. In this study, we observed no association of GV with rs1800450 (allelic P=
0.17, genotypic P= 0.20) or with any of the 15 SNPs spanning the MBL2 region
(chr10:54,520, 141–54,541,460).
NFE2L2
In 300 GV cases and 300 controls from China, Guan et al. (2008) reported an association
with the NFE2L2 5′-flanking SNP rs6721961 (−650C/A) (allelic P= 2.1E-05, genotypic P=
1.8E-04). SNP rs6721961 is not in HapMap and thus cannot be imputed; accordingly, we
analyzed 24 SNPs (19 imputed) spanning the NFE2L2 region (chr2:178,090, 03–
4178,139,859) and found no association.
PDGFRA-Kit
Xu et al. (2010) followed up a GV linkage signal (AIS4) at 4q12 detected in Chinese GV
families (Chen et al., 2005) by sequencing PDGRFA, identifying rare PDGRFA variants in
3.5% of familial GV cases versus 0.42% of controls (P= 8.0E-03), with no significant
difference (P= 5.3E-02) in sporadic vitiligo cases (1%) versus controls. In this study, we
observed no association with any of the 101 SNPs spanning the PDGFRA-KIT region
(chr4:55,085,263–55,611,5879). Nevertheless, genetic association studies have little power
to detect rare DNA sequence variants, and the majority of GV cases in the current study are
sporadic rather than familial.
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PTGS2
In 755 GV cases and 774 controls from China, Li K et al. (2009) reported an association
with the PTGS2 5′-flanking SNP rs689466 (−1195A>G) (allelic P= 1.4E-02, genotypic P=
4.0E-03). In this study, we observed no association with rs689466 (genotypic P= 0.10,
allelic P= 0.16), and the metaanalysis was not significant (meta-P= 0.27, OR= 1.03).
Overall, we observed no association with any of the 32 SNPs (25 imputed) spanning the
PTGS2 region (chr1:186,635,945–186,659,559).
STAT4
In 379 cases and 414 controls from China, Hu et al. (2010) reported an association of STAT4
SNP rs7574865 (genotypic P= 1.3E-02). In this study, rs7574865 did not achieve the study
significance threshold (genotypic P= 0.17, allelic P= 2.5E-02); similarly, meta-analysis was
not significant (meta-P= 1.1E-02, OR= 1.13). Overall, we observed no association with any
of the 27 SNPs spanning the STAT4 region (chr2:191,889,306–192,025,925).
TAP1-PSMB8
TAP1 and PSMB8 (previously, LMP7) are in close juxtaposition in the MHC class II region.
Casp et al. (2003) reported association of vitiligo with TAP1-PSMB8 in two independent US
non-Hispanic white cohorts: the first 230 cases and 188 controls (rs1135216, allelic P=
3.4E-03, Bonferroni-corrected P= 6.8E-03; genotypic P= 9.4E-03, Bonferroni-corrected P=
1.9E-02) and the second a family-based association study of 35 families (rs2071627, P=
5.7E-05, Bonferroni-corrected P= 1.1E-04). In this study, we observed no association with
rs1135216 (genotypic P= 0.19; allelic P= 8.5E-02, meta-P= 0.33, OR= 1.03); SNP
rs2071627 is not in HapMap and thus cannot be imputed. Overall, we tested 34 SNPs (15
imputed) spanning the TAP1-PSMB8 region (chr6:32,807,987–32,831,748), with the
strongest association observed for rs3819721 (P= 5.2E-06) and for rs6924102 (P= 9.4E-05).
However, as we previously demonstrated two major independent association signals in the
MHC class I and class II regions (HLA-A-HCG9 rs12206499 and HLA-DRB1/DQA1
rs532098; Jin et al., 2010a), we tested the association of rs3819721 and rs6924102 by nested
regression analysis accounting for LD with rs12206499 and rs532098; this analysis
indicated that the effects of TAP1-PSMB8 region SNPs reflect LD with these primary MHC
class I and class II association signals.
TGFBR2
In 233 GV cases and 415 controls from Korea, Yun et al. (2010) reported association with
TGFBR2 SNPs rs2005061 (codominant P= 6.0E-04), rs3773645 (recessive P= 1.2E-02), and
rs3773649 (recessive P= 6.9E-03), all Bonferroni corrected. In this study, we observed no
association with any of these SNPs, and meta-analysis was likewise generally not significant
(rs2005061 codominant P= 2.3E-02, meta-P= 0.39, OR= 1.02; rs3773645 recessive P= 0.35,
meta-P= 0.28, OR= 1.03; and rs3773649 recessive P= 0.42, meta-P= 9.0E-02, OR= 1.07).
Overall, we observed no association with any of the 66 SNPs (30 imputed) spanning the
TGFBR2 region (chr3:30,637,994–30,740,631).
TNF
In 176 cases and 545 controls from Iran, Namian et al. (2009) reported a genotypic
association of vitiligo with the TNF promoter SNP rs1800629 (genotypic P= 4.0E-04, allelic
P= 0.28), whereas Yazici et al. (2006) observed no association of vitiligo with rs1800629 in
61 cases and 123 controls from Turkey. In this study, SNP rs1800629 was excluded because
it deviated significantly from Hardy–Weinberg equilibrium in controls. Overall, we
observed no association with any of the 25 SNPs (18 imputed) spanning the TNF region of
the MHC (chr6:31,533,350–31,551,110). Several SNPs in the neighboring LTA gene showed
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evidence of association (rs1800683, P= 7.9E-05); however, nested regression analysis
comparing a model that included these LTA SNPs and the two major independent MHC
association signals (HLA-A-HCG9 rs12206499 and HLA-DRB1/DQA1 rs532098; Jin et al.,
2010a) indicated that the effects of LTA SNPs reflect LD with these primary MHC class I
and class II association signals.
TSLP
In 160 GV cases and 568 controls from Korea, Cheong et al. (2009) reported an association
with the TSLP 5′-flanking SNP rs3806933 (−847C>T) (allelic P= 1.7E-02, OR= 1.29,
genotypic P= 4.0E-03). In this study, we observed nominal significance for rs3806933
(allelic P= 2.1E-02, OR= 1.10) and for many neighboring SNPs (Supplementary Figure S2B
online), and meta-analysis of data for rs3806933 showed improved significance (meta-P=
3.1E-03, OR= 1.13), although the study significance threshold was not achieved. However,
among the 41 SNPs (29 imputed) analyzed spanning the TSLP region (chr5:110,358,245–
110,427,347), we observed association of GV with the promoter SNP rs764916 (P= 3.0E-4),
and with a cluster of nearby SNPs, located 6.5 kb upstream of the candidate SNP rs3806933
(Supplementary Figure S2B online). The difference in the signal location in non-Hispanic
whites versus Koreans may reflect the greater density of SNPs tested in this study as well as
ethnic differences.
TXNDC5
In 230 GV cases and 417 controls from Korea, Jeong et al. (2010a) reported an association
with the TXNDC5 SNP rs1043784 (codominant P= 3.5E-02). In this study, we observed no
association with rs1043784 (P= 0.34, meta-P= 0.10, OR= 1.09) or with any of the 18 SNPs
(11 imputed) spanning the TXNDC5 region (chr6:7,876,754–7,921,041).
UVRAG
In 225 vitiligo cases and 439 controls from Korea, Jeong et al. (2010b) reported association
with a haplotype defined by SNPs rs7933235 and rs1458836 (Bonferroni-corrected P=
3.0E-02). In this study, we observed no association with either of these SNPs (allelic P=
0.28 and P= 0.31, respectively) or with rs7933235–rs1458836 haplotypes (P= 0.59).
Overall, we observed no association with any of the 65 SNPs (21 imputed) spanning the
UVRAG region (chr11:75,516, 212–75,860,281).
VDR
In 31 GV cases and 33 controls from Romania, Birlea et al. (2006) reported an association
with the VDR restricted fragment length polymorphism rs7975232 (allelic P= 0.11,
genotypic P= 2.9E-02). In this study, we observed no association with rs7975232 (allelic P=
0.26, genotypic P= 0.31), and meta-analysis was also not significant (meta-P= 0.19, OR=
1.04). Overall, we observed no association with any of the 58 SNPs (34 imputed) spanning
the VDR region (chr12:48,230,322–48,308,814).
XBP1
Spritz et al. (2004) detected linkage of GV to microsatellites at 22q11–q11.22 in non-
Hispanic white families, and Liang et al. (2007) at 22q12 in Chinese families. Ren et al.
(2009) tested XBP1 as a positional/biological candidate gene within the linkage interval,
detecting association of SNP rs2269577 in 3 independent Han Chinese cohorts: 319 cases
and 294 controls (P= 7.0E-03, OR= 1.36), 365 cases and 404 controls (P= 8.0E-03, OR=
1.31), and 1,402 cases and 1,288 controls (P= 3.0E-03, OR= 1.18). In this study, we
observed association of GV with rs2269577 (P= 7.5E-04, OR= 1.17) and with 21 additional
SNPs of a total 39 examined (32 imputed) spanning the XBP1 region (chr22:29,154,237–
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29,219,122) (Supplementary Figure S2C online). Meta-analysis of rs2269577 data from the
three Chinese cohorts and the current study (Table 2) showed a consistent high-risk allele
across all four studies and strong evidence of association (meta-P= 9.5E-09, OR= 1.21) with
GV, with improved significance compared with meta-analysis of just the three Chinese
studies (P= 2.24E-06, OR= 1.24).
In the current data set, the lowest P-value across the XBP1 region was for SNP rs6005863
(P= 3.6E-04, OR= 1.17), located 35 kb upstream of the gene and correlated with rs2269577
(D′ = 0.96, r2= 0.58) (Supplementary Figure S2C online). Logistic regression analysis of the
seven most significant SNPs showed that the model including rs6005863 significantly
(P<1.5E-03) improved models that included any of the six other markers, whereas the model
including rs6005863 was not improved by inclusion of any of six other markers (namely,
rs5752809, rs7287806, rs5762788, rs6005881, rs5762795, and rs2269577). Taken together,
these findings support the association of GV with XBP1, possibly with the same causal
variant in both non-Hispanic whites and Han Chinese.
DISCUSSION
We analyzed SNP data for 33 GV candidate genes in a large non-Hispanic white case–
control data set that was subjected to stringent data and population quality control and
adjustment for population stratification in our previous GWAS (Jin et al., 2010a, b). This
resource provides 80% power to detect significant association with common alleles at ORs
in the range 1.20–1.25 across a wide range of allele frequencies.
We found evidence of primary genetic association with GV for only three of the candidate
genes tested, FOXP3, TSLP, and XBP1, all of which met the Bonferroni-corrected
significance thresholds adjusted on the basis of both the number of genes (0.05/33) and the
number of LD blocks (0.05/80) tested, although with marginal significance. Nevertheless,
the meta-analysis provided strong support for the association of GV with XBP1 (meta-P=
9.5E-09, OR= 1.21), with the pattern of associated SNPs indicating that the same causal
allele may exist in both the Chinese and the non-Hispanic white populations. In contrast,
association of GV with SNPs in the TAP1-PSMB8 region of the MHC seems to derive from
LD with primary association signals in the MHC class I and class II regions. Furthermore, as
suggested by several previous studies, the apparent association of GV with CTLA4 seems to
be secondary, driven by primary association of CTLA4 with other autoimmune diseases that
are epidemiologically associated with GV.
We also subjected the SNP data to permutation analysis to assess whether the observed P-
values were truly significant. The permutation analysis of SNP data for individual genes
generally supported significance for FOXP3 (rs3761547, P= 3.3E-02; rs11798415, P=
5.6E-03), TSLP (rs764916, P= 5.9E-03), and XBP1 (rs2269577, P= 1.8E-02; rs6005863, P=
8.0E-03). However, combined permutation analysis of SNP data for all 33 genes studied
failed to support the significance of any of the observed results. This may indicate that the
actual number of total LD blocks represented is much greater than 80, and a more
conservative Bonferroni-adjusted significance threshold would be more appropriate.
Alternatively, the combined permutation analysis may itself be too conservative, as several
of the genes tested are quite large (and thus are represented by a large number of SNPs) and
have only questionable status as valid biological candidate genes in the first place.
Finally, we observed no evidence of association of GV with SNPs tagging 28 of the 33
candidate genes tested: ACE, AIRE, CAT, CD4, CLEC11A, COMT, C12orf10, DDR1,
EDN1, ESR1, FAS, FBXO11, FOXD3, GSTM1, GSTT1, IL1RN, IL10, KITLG, MBL2,
NFE2L2, PDGFRA-KIT, PTGS2, STAT4, TGFBR2, TNF, TXNDC5, UVRAG, and VDR. In
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the case of FOXD3, this might reflect the involvement of the gene in only one unusual
family with both atypical presentation and inheritance of GV. In the case of PDGFRA, this
might reflect the inability of association methods to detect rare causal gene variants. For
many of the others, genetic association has previously only been tested by relatively small
studies carried out in populations other than non-Hispanic whites, and it is possible that
different populations have different causal variants. Nevertheless, it is widely recognized
that small case–control candidate gene association studies are very often flawed by
statistical fluctuation, inadequate correction for multiple testing, and population
stratification, and that the great majority of such reported “associations” are therefore
spurious (Hirschhorn et al., 2002; Freedman et al., 2004). Such studies must thus be
interpreted with great caution until validated by repeated replication or by studies that use
more robust methods. This analysis, by far the largest association study of GV candidate
genes ever carried out, failed to support the association of most candidate genes reported for
GV. Although our results do not completely exclude the possible involvement of these genes
in disease pathogenesis, our findings nevertheless underscore the extreme unreliability of
candidate gene studies in identifying true causal genes for disease susceptibility.
MATERIALS AND METHODS
Samples and genotypes
We used SNP genotype data from the genome-wide screening stage of the GV GWAS (Jin
et al., 2010a, b), comparing genotype data for 33 candidate loci in 1,392 unrelated non-
Hispanic white GV cases with 2,629 non-Hispanic white controls. Details of this case–
control cohort, quality control procedures, and correction of the data set for population
stratification, have been published previously (Jin et al., 2010a; dbGaP accession number
phs000224.v1.p1). All case study participants provided written informed consent, and the
study was approved by the Institutional Review Board at each participating center.
Statistical analyses
Association of SNPs within each region was tested by the Cochran–Armitage trend test
using PLINK, version 1.05 (http://pngu.mgh.harvard.edu/purcell/plink) (Purcell et al.,
2007). For each candidate SNP, we followed the analytical approach reported for each locus,
assuming at least one of trend (allelic test), genotypic, recessive, dominant, and codominant
models. Both OR and 95% confidence intervals were assessed by logistic regression using
PLINK. Analyses of X-chromosomal SNPs were performed by applying an algorithm that
combines independent allelic tests in males and females (Zheng et al., 2007); the resulting
test statistic Zmfa has an asymptotic X2 distribution with one degree of freedom when the
Hardy–Weinberg equilibrium holds in females. Calculations of LD between SNPs were
carried out using Haploview, version 4.1 (http://www.broadinstitute.org/haploview (Barrett
et al., 2005). For each region, we imputed SNPs that were not genotyped using MACH 1.0
(http://www.sph.umich.edu/csg/yli/mach/tour/) (Li et al., 2006), based on HapMap Phase II
and III data; all imputed SNPs had r2 values >0.3. Power calculations for individual studies
were performed using the genetic power calculator (Purcell et al., 2003). Meta-analysis was
performed by the Mantel–Haenszel method assuming a fixed effects model, assessing
heterogeneity across studies using the Q- and I2-statistics, where appropriate. We applied
stepwise logistic regression analysis within regions showing association with GV to
distinguish independent associations from secondary associations due to LD, assuming a
multiplicative effect for the high-risk allele of each SNP (Cordell and Clayton, 2002), using
STATA, version 10.0 (http://www.stata.com). Combined permutation analysis (10,000
iterations) of 30 of the loci tested (MHC loci TAP1-PSMB8, TNF, and DDR1 were not
included because of complex patterns of LD within the MHC), and permutation tests of each
individual locus were performed using the “max T perm” algorithm implemented in PLINK.
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Analyses of candidate genes
Using the non-Hispanic white genome-wide GV case–control data set (Jin et al., 2010a, b),
we analyzed 32 genomic regions containing previously reported candidate genes for GV
(ACE, AIRE, CAT, CD4, CLEC11A, COMT, CTLA4, C12orf10, DDR1, EDN1, ESR1, FAS,
FBXO11, FOXD3, GSTM1, GSTT1, IL1RN, IL10, KITLG, MBL2, NFE2L2, PDGFRA-KIT,
PTGS2, STAT4, TAP1-PSMB8, TGFBR2, TNF, TSLP, TXNDC5, UVRAG, VDR, and XBP1),
as well as FOXP3 as a previously unreported candidate gene. For each region, we analyzed
the candidate SNP, as well as neighboring SNPs spanning 10 kb upstream and 5 kb
downstream of the gene (based on NCBI build 37). Associations were assessed using a
gene-wise Bonferroni-adjusted significance threshold of P<1.52E-03 (0.05/33) and an LD
block-wise Bonferroni-adjusted significance threshold of P<6.25E-4 (0.05/80).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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